Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
View original at globenewswire.comGalera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement Combined company to operate as Obsidian Therapeutics, Inc…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Obsidian's pipeline and OBX-115 offer near-term, value creating milestones for Galera stockholders
60% confidenceOBX-115 offers an opportunity to provide patients with an improved TIL product and patient experience
60% confidenceCombined company's cash balance at closing is anticipated to fund operations into the second half of 2028
60% confidenceTopline data from melanoma registration-enabling trial expected by year-end 2027
60% confidencePhase 1 data from the ongoing NSCLC trial expected in the first half of 2027
60% confidenceThe transaction with Obsidian is the best path forward for Galera
60% confidenceThe transaction and support from leading life sciences investors will allow Obsidian to advance development plans for OBX-115 in melanoma and NSCLC
60% confidenceAt Obsidian, they are striving to deliver a best-in-class TIL cell therapy developed using their proprietary protein-regulation technology
60% confidence